Nephropathy News and Research

RSS

Nephropathy is a broad medical term used to denote disease or damage of the kidney, which can eventually result in kidney failure. The primary and most obvious functions of the kidney are to excrete any waste products and to regulate the water and acid-base balance of the body – therefore loss of kidney function is a potentially fatal condition.

High rates of type 1 diabetes in Australian children

According to a new report the rate of Type 1 diabetes in Australian children will leap by 10 per cent in the five years to 2013, cementing Australia's position in the top 10 OECD nations for the condition's prevalence. Currently the prevalence of diabetes in Australia ranks seventh-highest among the 30 OECD nations.

17 Jun 2011

Phosphate regulating hormone associated with increased risk of kidney failure and death among CKD patients

A high level of a hormone that regulates phosphate is associated with an increased risk of kidney failure and death among chronic kidney disease (CKD) patients, according to a recent study led by researchers at the University of Miami and funded by the National Institute of Diabetes and Digestive Diseases and Kidney Diseases (NIDDK) at the National Institutes of Health.

16 Jun 2011

Overactive mTOR can result in serious disruption of kidney filter in diabetes patients

Diabetes mellitus is one of the most common secondary diseases in modern society. And because it is on the rise, it is also one of the greatest challenges facing medicine today. Diabetes patients do not die as a direct result of the increase in blood sugar, but from the long-term complications of their disease, in which the increase in blood sugar causes damage to blood vessels and organs.

15 Jun 2011

High FGF-23 hormone levels linked to increased risk of end-stage renal disease and death

Patients in the early stages of chronic kidney disease who had elevated levels of the endocrine hormone fibroblast growth factor 23 (that regulates phosphorus metabolism) had an associated increased risk of end-stage renal disease and death, according to a study in the June 15 issue of JAMA.

15 Jun 2011

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it successfully completed patient enrollment in its phase II Contrast-Induced Acute Kidney Injury study with its oral drug candidate CRMD001.

14 Jun 2011

Oncogene Aurora A may contribute to polycystic kidney disease

The Aurora A kinase may contribute to polycystic kidney disease (PKD) by inactivating a key calcium channel in kidney cells, according to a study in the June 13 issue of The Journal of Cell Biology.

13 Jun 2011

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Alexion Pharmaceuticals, Inc. today announced the presentation of research that provides further insight into the clinical consequences of paroxysmal nocturnal hemoglobinuria (PNH), and positive impact of Soliris® (eculizumab) therapy on long-term outcomes.

13 Jun 2011

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Alexion Pharmaceuticals, Inc. today announced the presentation of final data from the two Phase 2 studies of Soliris as a treatment for patients with atypical hemolytic uremic syndrome.

13 Jun 2011

IBC now qualified as 'patient-centered medical homes'

Independence Blue Cross (IBC) has reached a significant milestone with 100 primary care practices with more than 1,000 physicians now qualified as "patient-centered medical homes," and announced today that it is stepping up its efforts to support this transformation of primary care.

10 Jun 2011

Research provides new insights into how cilia are assembled on the cell surface

Body cells detect signals that control their behavior through tiny hairs on the cell surface called cilia. Serious diseases and disorders can result when these cilia do not work properly.

9 Jun 2011

Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced clinical and preclinical data from its lead program, KAI-4169, at the Endocrine Society's 93rd Annual Meeting (ENDO 2011) taking place in Boston, June 4-7, 2011. KAI-4169 is a novel pharmaceutical agent being developed for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).

7 Jun 2011

Higher than IOM recommended Vitamin D levels required for optimizing osteoporosis, low BMD therapy

To fully optimize a drug therapy for osteoporosis and low bone mineral density (BMD), patients should maintain vitamin D levels above the limits recently recommended by the Institute of Medicine (IOM), according to a new study by researchers from Hospital for Special Surgery in New York. The study will be presented at the Endocrine Society's Annual Meeting in Boston, June 4-7.

7 Jun 2011

Scientists find way to protect kidney from cancer drug toxicity

Scientists may have a way to make the powerful cancer drug cisplatin less toxic to the kidneys and more effective against some cancers.

4 Jun 2011

HbA1c glucose monitoring test not effective for diagnosing diabetes patients with kidney failure

The gold standard long-term glucose monitoring test for patients with diabetes proved to be of limited value in dialysis patients, according to a new study at Wake Forest Baptist Medical Center.

1 Jun 2011

Pre-implantation genetic diagnosis can avoid mother to child transmission of mtDNA disorders

Dutch researchers have developed a test which predicts which mothers at risk of passing on mitochondrial genetic disease to their children are likely to have a healthy baby.

30 May 2011

There's no upper age limit for balloon angioplasties

Loyola University Health System interventional cardiologist Dr. Ferdinand Leya says there's no upper age limit for performing balloon angioplasties.

26 May 2011

Galectin-3 research uncovers new use for Modified Citrus Pectin in cardiovascular, heart disease

In a new important research study out of the UK, scientists found that the specific form of Modified Citrus Pectin developed by Isaac Eliaz, M.D. interrupts deadly kidney fibrosis by binding to galectin-3 molecules, decreasing the effects of inflammation and fibrosis in acute kidney injury.

24 May 2011

Researchers replicate progression of inflammatory gene changes of kidney from mild to severe diabetic nephropathy

University of Louisville researchers have replicated the inflammatory gene changes of a human kidney as it progresses from mild to severe diabetic nephropathy, using a mouse model developed by a UofL researcher, according to an article published today in the journal Experimental Nephrology. Diabetic nephropathy is the foremost cause of kidney failure.

24 May 2011

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Relypsa, Inc. today announced the presentation of positive results from a Phase 2 clinical trial of the company's lead compound, RLY5016, a non-absorbed oral potassium binder being developed as a treatment for hyperkalemia (elevated serum potassium levels).

23 May 2011

Cholesterol drug may help treat mitochondrial diseases

A human drug that both prevents and cures kidney failure in mice sheds light on disabling human mitochondrial disorders, and may represent a potential treatment in people with such illnesses.

20 May 2011

Nephropathy News and Research

Further Reading

High rates of type 1 diabetes in Australian children

Phosphate regulating hormone associated with increased risk of kidney failure and death among CKD patients

Overactive mTOR can result in serious disruption of kidney filter in diabetes patients

High FGF-23 hormone levels linked to increased risk of end-stage renal disease and death

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

Oncogene Aurora A may contribute to polycystic kidney disease

Study reveals positive impact of Soliris on long-term outcomes in PNH patients

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

IBC now qualified as 'patient-centered medical homes'

Research provides new insights into how cilia are assembled on the cell surface

Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011

Higher than IOM recommended Vitamin D levels required for optimizing osteoporosis, low BMD therapy

Scientists find way to protect kidney from cancer drug toxicity

HbA1c glucose monitoring test not effective for diagnosing diabetes patients with kidney failure

Pre-implantation genetic diagnosis can avoid mother to child transmission of mtDNA disorders

There's no upper age limit for balloon angioplasties

Galectin-3 research uncovers new use for Modified Citrus Pectin in cardiovascular, heart disease

Researchers replicate progression of inflammatory gene changes of kidney from mild to severe diabetic nephropathy

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Cholesterol drug may help treat mitochondrial diseases

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News